Calendario›SNY›SAR447971

SAR447971

SAR447971 First-in-human Study

Ensayo de Sanofi en Hidradenitis · Healthy Volunteers (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

114

previstos

Centros

1

Fin del objetivo primario

feb 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en may 2026.

Qué mide

SAD20411: Incidence of treatment emergent adverse events (TEAEs) (del registro, en inglés) (del dia 1 al dia 15)

Cómo lo describe el promotor

En el documentoEn inglés, del registroSAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation. MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants. MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants. Number of participants - The total expected number of healthy participants is approximately 94 and the total number of HS participants is expected to be approximately 20. * SAD20411 will enroll up to 46 participants * MAD20412 will enroll up to 48 participants * MAD24339 will enroll up to 20 participants Duration of study - The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07629336), actualizada en jun 2026.